Clearside Biomedical, Inc.
US ˙ NasdaqGM ˙ US1850631045

Introduction

This page provides a comprehensive analysis of the known insider trading history of John Crumpler. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate John Crumpler has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PHAS / PhaseBio Pharmaceuticals Inc 10% Owner 0
US:GTHX / G1 Therapeutics, Inc. 10% Owner 3,237,711
US:CLSD / Clearside Biomedical, Inc. 10% Owner 2,060,514
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by John Crumpler. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CLSD / Clearside Biomedical, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CLSD / Clearside Biomedical, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2016-06-07 CLSD Hatteras Venture Advisors IV SBIC, LLC 414,286 7.0000 414,286 7.0000 2,900,002 126 24.7200 7,341,148 253.14
2016-06-07 CLSD Hatteras Venture Advisors III, LLC 107,142 7.0000 107,142 7.0000 749,994

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CLSD / Clearside Biomedical, Inc. Insider Trades
Insider Sales CLSD / Clearside Biomedical, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CLSD / Clearside Biomedical, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2017-01-19 CLSD Hatteras Venture Advisors IV SBIC, LLC 7,592 8.2200 7,592 8.2200 62,406 334 5.7800 -18,524 -29.68
2017-01-19 CLSD Hatteras Venture Advisors III, LLC 6,478 8.2200 6,478 8.2200 53,249
2017-01-18 CLSD Hatteras Venture Advisors IV SBIC, LLC 12,258 8.6400 12,258 8.6400 105,909
2017-01-18 CLSD Hatteras Venture Advisors III, LLC 10,457 8.6400 10,457 8.6400 90,348
2017-01-17 CLSD Hatteras Venture Advisors IV SBIC, LLC 9,806 8.9200 9,806 8.9200 87,470
2017-01-17 CLSD Hatteras Venture Advisors III, LLC 8,366 8.9200 8,366 8.9200 74,625
2016-06-07 CLSD Hatteras Venture Advisors IV SBIC, LLC 69 7.0000 69 7.0000 483
2016-06-07 CLSD Hatteras Venture Advisors III, LLC 69 7.0000 69 7.0000 483

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CLSD / Clearside Biomedical, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by John Crumpler as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -226,061 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -24,709 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
C - Conversion -272,107 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -40,420 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -13,558 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -149,320 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -94,874 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
C - Conversion -1,044,764 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock
C - Conversion -13,609 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock
C - Conversion -174,699 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -4,846 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -3,862 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -42,530 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
C - Conversion -52,690 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -994 40,420 -2.40 5.00 -4,970 202,100
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 41,414 41,414 0.12 4,970 4,970
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -41,414 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -104 13,558 -0.76 5.00 -520 67,790
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 4,309 13,662 46.07 0.12 517 1,639
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -4,309 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
S - Sale -1,139 149,320 -0.76 5.00 -5,695 746,600
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
X - Other 47,458 150,459 46.08 0.12 5,695 18,055
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
X - Other -47,458 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
S - Sale -42 94,874 -0.04 5.00 -210 474,370
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
X - Other 1,731 94,916 1.86 0.12 208 11,390
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
X - Other -1,731 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
S - Sale -458 1,044,764 -0.04 5.00 -2,290 5,223,820
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
X - Other 19,061 1,045,222 1.86 0.12 2,287 125,427
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
X - Other -19,061 0 -100.00
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 150,000 416,481 56.29 5.00 750,000 2,082,405
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 266,481 266,481
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 4,846 4,846
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 12,487 163,099 8.29 5.00 62,435 815,495
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 150,612 150,612
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
P - Purchase 137,513 1,820,933 8.17 5.00 687,565 9,104,665
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 1,683,420 1,683,420
2018-10-24 2018-10-22 4 PHAS PhaseBio Pharmaceuticals Inc
Common Stock
C - Conversion 52,690 52,690
2018-06-01 2018-05-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -41,710 3,237,711 -1.27 48.00 -2,002,080 155,410,128
2018-06-01 2018-05-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -758,290 3,279,421 -18.78 48.00 -36,397,920 157,412,208
2018-05-23 2018-05-23 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -26 4,037,711 0.00 50.50 -1,313 203,904,406
2018-05-23 2018-05-23 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -474 4,037,737 -0.01 50.50 -23,937 203,905,718
2018-05-23 2018-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -308 4,038,211 -0.01 50.69 -15,611 204,677,128
2018-05-23 2018-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -5,592 4,038,519 -0.14 50.86 -284,405 205,396,249
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -26 4,044,111 0.00 52.13 -1,355 210,819,506
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -474 4,044,137 -0.01 52.13 -24,710 210,820,862
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -1,595 4,044,611 -0.04 51.06 -81,439 206,513,389
2018-05-23 2018-05-21 4 GTHX G1 Therapeutics, Inc.
Common Stock
S - Sale -29,005 4,046,206 -0.71 51.16 -1,483,907 207,005,517
2017-12-04 2017-11-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
J - Other 995 4,075,211 0.02
2017-12-04 2017-11-30 4 GTHX G1 Therapeutics, Inc.
Common Stock
J - Other -99,513 4,074,216 -2.38
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1,009,693 0 -100.00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -2,584,959 0 -100.00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -6,568,527 0 -100.00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Series 1 Preferred Stock
C - Conversion -1,318,681 0 -100.00
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
P - Purchase 133,333 3,861,797 3.58 15.00 1,999,995 57,926,955
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
C - Conversion 99,513 99,513
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
C - Conversion 212,419 212,419
2017-05-24 2017-05-22 4 GTHX G1 Therapeutics, Inc.
Common Stock
C - Conversion 3,728,464 3,728,464
2017-01-19 2017-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -7,592 2,060,514 -0.37 8.22 -62,406 16,937,425
2017-01-19 2017-01-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -12,258 2,068,106 -0.59 8.64 -105,909 17,868,436
2017-01-19 2017-01-17 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -9,806 2,080,364 -0.47 8.92 -87,470 18,556,847
2017-01-19 2017-01-19 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -6,478 1,757,719 -0.37 8.22 -53,249 14,448,450
2017-01-19 2017-01-18 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -10,457 1,764,197 -0.59 8.64 -90,348 15,242,662
2017-01-19 2017-01-17 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -8,366 1,774,654 -0.47 8.92 -74,625 15,829,914
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -21,705 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series C Preferred Stock
C - Conversion -337,897 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series B Preferred Stock
C - Conversion -432,941 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A-1 Preferred Stock
C - Conversion -689,388 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A Preferred Stock
C - Conversion -2,035,908 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 414,286 2,090,170 24.72 7.00 2,900,002 14,631,190
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -69 1,675,884 0.00 7.00 -483 11,731,188
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
X - Other 21,705 1,675,953 1.31 0.02 478 36,871
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
C - Conversion 1,598,223 1,654,248 2,852.70
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -1,805 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy)
X - Other -19,900 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series C Preferred Stock
C - Conversion -337,898 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series B Preferred Stock
C - Conversion -432,940 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A-1 Preferred Stock
C - Conversion -689,388 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Series A Preferred Stock
C - Conversion -2,035,907 0 -100.00
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
P - Purchase 107,142 1,783,020 6.39 7.00 749,994 12,481,140
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
S - Sale -69 1,675,878 0.00 7.00 -483 11,731,146
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
X - Other 21,705 1,675,947 1.31 0.02 478 36,871
2016-06-07 2016-06-07 4 CLSD Clearside Biomedical, Inc.
Common Stock
C - Conversion 1,598,219 1,654,242 2,852.79
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,050
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
2016-06-01 3 CLSD Clearside Biomedical, Inc.
Common Stock
112,046
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)